Thursday, 15 October 2026European Markets

ASETEK Stock Bullish Momentum With A 27% Rise So Far On Monday

Loading stream...

(VIANEWS) - Shares of ASETEK (Oslo Børs Benchmark Index_GI: ASTK.OL) rose by a staggering 27.41% to kr4.23 at 14:22 EST on Monday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is falling 0.41% to kr1,220.38, following the last session's upward trend. This seems, so far, a somewhat down trend trading session today.

About ASETEK

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.73.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ASETEK's stock is considered to be overbought (>=80).

More news about ASETEK (ASTK.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com